AUS
NZ
UK
CA
USA
IND
Highlights
- Shineco partners with BICC to advance blockchain-powered compliance and management tools.
- Collaboration supports digital lifecycle management of mesenchymal stem cells on Ethereum.
- Agreement builds on Shineco’s ongoing expansion in digital health innovation.
Shineco Inc (NASDAQ:SISI) operates within the biotechnology sector and continues to explore new methods of integrating digital solutions into life sciences. The company has broadened its approach by combining advanced healthcare research with blockchain technology, aiming to enhance transparency, efficiency, and regulatory alignment across its operations. This expansion reflects a growing emphasis on digital tools within the biotech industry, particularly in areas of compliance and secure data management.
Biotechnology Focus and Core Operations
Shineco announced a cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote and expand blockchain applications in the health and life sciences sector. The partnership is designed to integrate on-chain modules and compliance tools into Shineco’s business, ensuring regulatory standards remain a central part of its digital strategy. The collaboration also extends to working with technical partners to strengthen the integration of blockchain-based platforms in managing sensitive biomedical processes.
Role of Plus Me in Digital Management
As part of this initiative, Plus Me will provide complete digital lifecycle management for Shineco’s compliant mesenchymal stem cells on the Ethereum mainnet. This framework incorporates blockchain to ensure traceability, security, and compliance throughout the management process. By applying blockchain protocols, Shineco aims to secure and monitor every stage of digital operations associated with stem cell management. The integration of Plus Me’s expertise highlights the company’s dedication to combining biotechnology with emerging digital innovations.
Building on Previous Initiatives
The collaboration with BICC builds on Shineco’s earlier decision to establish a Cell Digital Division. This division focuses on exploring opportunities within digital ecosystems to support and manage biomedical assets. By creating a dedicated unit, the company has positioned itself to better incorporate blockchain technology into its biotechnology solutions. The agreement with BICC reinforces Shineco’s commitment to expanding its digital health initiatives while ensuring regulatory compliance and operational efficiency.
Expanding Digital Health Capabilities
Through the partnership, Shineco continues to enhance its role in bridging biotechnology and blockchain technology. The agreement provides a foundation for integrating advanced compliance tools into the management of biomedical products, supporting the secure and transparent handling of critical assets. As the company advances in its digital health strategy, blockchain remains a key driver of innovation, enabling Shineco to strengthen its operational structure in biotechnology and healthcare-related services.
